Five Prime Presents Preclinical Research Data on CSF-1R and PD-1 Blockade at the 2017 AACR Annual Meeting
April 03 2017 - 8:00AM
Five Prime Therapeutics, Inc. (Nasdaq:FPRX), a clinical-stage
biotechnology company focused on discovering and developing
innovative immuno-oncology protein therapeutics, announced that a
poster featuring preclinical data related to Five Prime’s CSF-1R
antibody, cabiralizumab (FPA008), was presented today at the 2017
American Association for Cancer Research (AACR) Annual Meeting in
Washington, D.C. The poster titled “Antibody-Based Inhibition of
CSF-1R as a Component of Combination Immunotherapy in Preclinical
Models” is available at
http://www.fiveprime.com/news-media/publications-presentations.
“These preclinical findings suggest that the surrogate antibody
for FPA008 significantly reduces tumor growth in murine syngeneic
tumor models when administered alone and when administered in
combination with a PD-1 antibody,” said Kevin Baker, Ph.D., Senior
Vice President of Development Sciences at Five Prime. “These
findings support previous preclinical data that served as the basis
for our Phase 1a/1b clinical trial that we are running in
collaboration with Bristol-Myers Squibb (BMS) to investigate the
use of cabiralizumab in combination with nivolumab (anti-PD-1,
OPDIVO®) in six different tumor types.”
The colony stimulating factor 1 receptor (CSF-1R) signaling
pathway promotes tumor progression via the recruitment,
differentiation, and survival of immuno-suppressive, M2 polarized,
tumor-associated macrophages (TAMs). Five Prime has developed
cabiralizumab (FPA008), an IgG4 antibody against CSF-1R that blocks
the ability of both CSF-1 and IL-34 to bind and activate this
receptor, thereby modulating the immune response to
tumorigenesis.
Five Prime has identified alterations in the tumor
microenvironment that occur upon CSF-1R inhibition, including
significant reduction of immunosuppressive M2 TAMs and an increase
in tumor PD-L1 expression. Notably, when dosing in combination, the
blockade of CSF-1R and PD-1/PD-L1 results in a significant increase
in CD8+ T cells within the tumor. The results show that, when added
to PD-1/PD-L1 blockade, the surrogate antibody for FPA008 can
significantly enhance anti-tumor efficacy.
About Five Prime
Five Prime Therapeutics, Inc. discovers and develops innovative
therapeutics to improve the lives of patients with serious
diseases. Five Prime's comprehensive discovery platform, which
encompasses virtually every medically relevant extracellular
protein, positions it to explore pathways in cancer, inflammation
and their intersection in immuno-oncology, an area with significant
therapeutic potential and a growing focus of the company's R&D
activities. Five Prime has entered into strategic collaborations
with leading global pharmaceutical companies and has promising
product candidates in clinical and late preclinical development.
For more information, please visit www.fiveprime.com.
Cautionary Note on Forward-looking
StatementsThis press release contains forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995. Words such as "may," "will," "expect," "plan,"
"anticipate," "estimate," "intend" and similar expressions (as well
as other words or expressions referencing future events, conditions
or circumstances) are intended to identify forward-looking
statements. These forward-looking statements are based on Five
Prime's expectations and assumptions as of the date of this press
release. Each of these forward-looking statements involves risks
and uncertainties. Actual results may differ materially from these
forward-looking statements. Factors that may cause actual results
to differ from those expressed or implied in the forward-looking
statements in this press release are discussed in Five Prime's
filings with the U.S. Securities and Exchange Commission, including
the "Risk Factors" contained therein. Except as required by law,
Five Prime assumes no obligation to update any forward-looking
statements contained herein to reflect any change in expectations,
even as new information becomes available.
CONTACTS:
Heather Rowe
Investor Relations
415-365-5737
heather.rowe@fiveprime.com
Five Prime Therapeutics (NASDAQ:FPRX)
Historical Stock Chart
From Apr 2024 to May 2024
Five Prime Therapeutics (NASDAQ:FPRX)
Historical Stock Chart
From May 2023 to May 2024